Brian Skorney — Podcast Appearances & Summaries

Featured On 1 Podcast

Biotech Hangout

10 episodes

All Appearances

10 episodes

Episode 199 - October 16, 2026

Biotech Hangout

Oct 16, 202659 minBiotech analyst

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 199 examines the XBI's 700 basis-point two-week decline, record hedge fund degrossing over five years, three new IPOs raising $467M combined, Bristol Myers Squibb's nuanced IPF phase three results, celiac disease emerging as a competitive therapeutic battleground, and Moderna's cancer vaccine data ahead of ESMO. → KEY INSIGHTS - **Degrossing Cycle:** Goldman Sachs prime broker data shows hedge funds unwound biotech positions in six of the past eight weeks, representing the largest cumulative degrossing in over five years. Long-short funds cutting gross exposure from $2B to $1.5B create cascading forced selling across crowded trades, making buying pressure unlikely until after October 31 annual fund closes. - **IPO Market Resilience:** Despite XBI correcting roughly 700 basis points from its $169 August high, 28 biotechs have debuted in 2026, with T-Rex Bio, Iambic Therapeutics, and Citi Therapeutics raising a combined $467M this week alone. Private companies with near-term clinical catalysts and technological differentiation continue to access capital at reasonable valuations regardless of broader sector weakness. - **M&A as the Likely Catalyst:** Analysts identify M&A activity as the primary mechanism to reverse the current biotech bear cycle, not time or rate cuts alone. A string of acquisitions would generate FOMO among sidelined investors who recognize undervalued assets but fear catching a falling knife without external validation that bargain prices have arrived. - **Celiac Disease Competitive Landscape:** Three companies — Teva, Argenx, and FirstTrax — are targeting IL-15 biology in celiac disease with early data showing reductions in intraepithelial lymphocytes and histological improvement across all programs. The pivotal commercial debate centers on reimbursement justification when gluten avoidance is free, making endpoint selection between histology and symptoms critical for regulatory and payer strategy. - **Brain Shuttle Transferrin Momentum:** Arrowhead achieved over 80% tau lowering in CSF using a transferrin-conjugated siRNA antibody drug conjugate, becoming the first to demonstrate clinical data in this modality. Investors tracking CNS RNAi should monitor tau PET reduction data, not just CSF biomarkers, since Biogen's phase 2b showed CSF reductions substantially exceeding PET signal changes. → NOTABLE MOMENT Argenx's Sjogren's phase three trial failed a futility analysis that investors did not know existed, blindsiding analysts who had just concluded a bullish physician panel on the indication hours earlier — illustrating how undisclosed interim analyses can instantly invalidate consensus positioning. 💼 SPONSORS None detected 🏷️ Biotech Market Correction, Hedge Fund Degrossing, IPF Drug Development, Cancer Vaccines mRNA, CNS Drug Delivery

Read Full Summary Listen

Episode 198 - October 2, 2026

Biotech Hangout

Oct 2, 202660 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 198 covers Q3 2026 biotech market performance with XBI up 27% year-to-date, major BD deals including Regeneron-Sanofi's $8B INI collaboration and AstraZeneca's $2B Summit equity investment, FDA approvals for FOP and Parkinson's treatments, and clinical data from WCLC and EASD conferences covering lung cancer and GLP-1 obesity therapies. → KEY INSIGHTS - **XBI Sector Divergence:** The XBI's 27% YTD gain masks severe underlying dispersion — heavily shorted, under-owned names like Moderna, Iovance, and Summit propped up the index while broadly held specialist fund positions declined sharply. Investors should monitor Morgan Stanley prime broker dispersion data to distinguish index-level performance from actual portfolio exposure, as the two have diverged significantly since late August's $169 XBI peak. - **Dupixent Patent Extension:** Sanofi's CFO signaled the Dupixent composition-of-matter patent could extend from 2031 to approximately late 2037, aligning with independent patent analysis. Investors tracking IL-4/IL-13 pathway assets should factor this extended runway into LOE modeling. The Regeneron-Sanofi deal adds four next-generation antibodies — including an IL-13 lead, a bispecific, a "super dupey," and a long-acting IL-4 — targeting less frequent dosing to preempt biosimilar competition. - **Summit-AstraZeneca Deal Structure:** AstraZeneca's $2B equity stake at a premium in Summit Therapeutics represents a novel deal structure where the strategic partner co-funds R&D trials — a structure rarely seen in PD-1/VEGF collaborations. Investors should watch the Harmony 3 trial readout on vunicimab for PFS data with a directional OS signal; an "immature OS" comment at readout would likely be interpreted negatively by the market. - **GLP-1 Weight Loss Benchmarks:** Lilly's retatrutide (GLP-1/GIP/glucagon triple agonist) achieved 21% weight loss in diabetic patients at 80 weeks in the TRIUMF-2 trial, crossing a threshold considered difficult in this population. A separate tirzepatide-amylin combination showed 23.3% weight loss at 48 weeks but carried a 27% discontinuation rate versus 3% for tirzepatide alone — a safety signal that regulators and competitors developing combination obesity therapies should weigh carefully. - **Gene Therapy Durability Risk:** Unicure's Huntington's disease gene therapy AMT-130 showed disease progression slowing drop from 75% at the prior update to 44% at four years, sending shares down 37% in a single session. Investors evaluating gene therapy assets should stress-test durability assumptions across multi-year follow-up periods, as early efficacy signals in phase 1/2 studies may not hold, particularly in CNS indications where delivery and expression consistency remain unresolved challenges. - **China Biotech Deal Velocity:** Three China-originated biotech deals closed in one week: Novo Nordisk paid $300M upfront plus $2.6B for Henri's GLP-1/GIP bispecific, Merck paid $400M upfront plus $2.13B for Cybranch's oral KRAS G12D inhibitor, and Novartis paid $575M upfront plus $7.2B for Avogene's mRNA CD19/CD3 T-cell engager. Investors tracking oncology and metabolic disease pipelines should monitor Chinese biotechs as a consistent source of late-stage licensing targets. → NOTABLE MOMENT Emix Biopharma reported an 89% complete response rate for its BCMA CAR-T in AL amyloidosis — a disease with no approved therapies and current CR rates of 5–35% — yet the stock fell nearly 10% on the day because the company simultaneously announced a concurrent follow-on financing, locking in price and eliminating upside momentum from the data. 💼 SPONSORS None detected 🏷️ XBI Market Performance, GLP-1 Obesity Therapies, PD-1 VEGF Bispecifics, Gene Therapy Durability, China Biotech Licensing, Rare Disease Drug Approvals

Read Full Summary Listen

Episode 195 - September 11, 2026

Biotech Hangout

Sep 15, 202660 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 195 covers a turbulent week for biotech markets driven by oil-price inflation and rising Treasury yields, alongside major FDA leadership confirmations, Novartis's dual Phase 3 failures in LP(a) reduction and DM1, positive Phase 2 data from Roivant in pulmonary hypertension, and emerging oral amylin weight-loss data from Structured Therapeutics. → KEY INSIGHTS - **FDA Stabilization Signal:** The permanent appointments of Michael Davis at CDER and Kareem Mikhail at CBER mark a shift toward regulatory predictability after five CDER director turnovers since 2025. Mikhail has explicitly framed his role as a "conductor" rather than a unilateral decision-maker, signaling a return to scientific consensus-driven approvals. Biotech investors should monitor Davis's stance on compounded GLP-1s and psychedelics as near-term policy indicators. - **LP(a) Cardiovascular Thesis Weakens:** Novartis's Horizon trial, enrolling ~8,000 patients with average LDL of 60–65, produced a fully negative outcome for pelicarcen despite 80% LP(a) reduction. The failure pattern—slower-than-modeled event rates—mirrors early signals in Amgen's ongoing LP(a) trial. Investors tracking Amgen and Lilly's LP(a) programs should treat mismodeled event pacing as a leading indicator of likely trial failure, not a neutral operational footnote. - **DM1 Modality Risk—ASO vs. siRNA:** Novartis's Avidity-derived siRNA drug failed its Phase 3 VHOT endpoint in DM1, raising questions about whether cytoplasmic siRNA mechanisms can effectively silence nuclear-retained DMPK RNA. Dyne Therapeutics' ASO approach shows ~25% placebo-adjusted CASI-22 splice correction, a mechanistically more appropriate modality for nuclear targets. Expansion cohort data from Dyne arrives early next year and now carries higher strategic significance. - **Large-Cap M&A Pricing Risk:** Novartis's $12B Avidity acquisition, which modeled ~$6B peak sales, is now facing activist pressure from Artisan Partners demanding board restructuring and compensation reform. Analysis shows large-cap pharma deals routinely inflate revenue projections in SEC filings to justify multiples. A portfolio strategy of six smaller, earlier-stage acquisitions targeting ~35–40% probability of success outperforms single high-conviction late-stage bets priced at near-certainty multiples. - **Roivant's PHILD Phase 2 Outperformance:** Roivant's inhaled soluble guanylate cyclase agonist (in-licensed from Bayer) achieved a 56% pulmonary vascular resistance reduction and 36-meter six-minute walk improvement at 16 weeks, reaching ~50 meters by 48 weeks in PHILD patients. Phase 3 was already enrolling at data release. With low cough burden versus competitor Tyvaso and a ~$2.5B addressable market at modest penetration, the program represents a concrete execution benchmark for rare pulmonary disease development timelines. - **Biotech Rate Sensitivity—Threshold Matters:** XBI declined ~3% during a week where Brent crude exceeded $108/barrel and 10-year Treasuries approached 5%, driven by US-Iran conflict. Rate sensitivity in biotech is not linear—25-basis-point moves have minimal sector impact, but multi-hundred-basis-point escalation cycles (as seen in 2022–2023) compress valuations structurally. Investors should track Fed funds trajectory over 12-month windows, not individual meeting decisions, as the relevant macro signal for biotech allocation. → NOTABLE MOMENT Novartis released two separate Phase 3 failures—LP(a) and DM1—over a single Labor Day weekend, both after market close on a Friday. The DM1 failure directly impaired a $12B acquisition completed less than a year prior, triggering an activist letter and prompting analysts to cut long-term EPS growth forecasts by approximately 200 basis points. 💼 SPONSORS None detected 🏷️ LP(a) Cardiovascular Trials, FDA Leadership Appointments, DM1 Gene Silencing, Pulmonary Hypertension PHILD, Biotech M&A Strategy, Oral Amylin Weight Loss

Read Full Summary Listen

Episode 192 - August 7, 2026

Biotech Hangout

Aug 7, 202664 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 192 covers Q2 earnings season performance across biotech, the AstraZeneca-Bristol Myers merger speculation, 17 IPOs in 2026 with strong post-debut trading, reverse merger trends, FDA regulatory decisions on Miriam and Praxis drugs, Replimmune's approval, and US-China clinical trial competitiveness concerns raised by Strand CEO Jake Beecroft. → KEY INSIGHTS - **Mega-merger risk for biotech ecosystems:** When large pharma companies merge, R&D uncertainty persists for 18-plus months, capital gets locked away from strategic partnerships, and one fewer business development partner exists for smaller biotechs. The BMS-Celgene merger is a documented case study where previously active deal-making with early-stage companies like Strand effectively froze for over a year post-announcement, reducing innovation funding across the sector. - **Reverse merger viability with PIPE structure:** Reverse mergers into shell companies are now a credible IPO alternative when paired with a simultaneous PIPE from a tier-one investor syndicate. This combination lets private biotechs control their shareholder base, move faster than a traditional IPO, and recapitalize rather than simply inherit legacy shareholders. Historical successes include Madrigal, Chinook (acquired by Novartis for $3.2B), and Alpine (acquired by Vertex for $4.9B). - **US clinical trial inefficiency vs. Australia benchmark:** Australia runs four times more first-in-human trials than the US despite having one-tenth the population. The gap stems from disconnected institutional nodes, outdated IRB processes, and years of deferred regulatory reform — not population size. FDA's Operation Trialblazer initiative aims to smooth first-in-human pathways, but a full Australia-style accelerated trial system requires an act of Congress to implement. - **IgAN disease progression halted in two-year trial:** Otukapu's VOIXACT showed eGFR improvement from baseline over 24 months in a 510-patient IgAN study — a result not previously seen in two-year kidney disease trials. The drug demonstrated a placebo-like safety profile with large separation from the control arm. IgAN is the third leading cause of kidney failure globally after diabetes and hypertension, making this dataset a potential standard-of-care shift. - **FDA conservatism on Miriam's volexibat creates strategic precedent:** The FDA requested a Phase 3 study for volexibat in PSC despite the drug showing statistically significant pruritus reduction in a disease with zero approved treatments. The same FDA division approved GSK's Linarixibat in the comparable PBC indication earlier in 2026 with a less pronounced effect. Biotech companies in rare cholestatic liver disease should anticipate heightened evidentiary requirements even when no competitive approved therapy exists. - **Crossover investors now essential for IPO execution:** The traditional VC-to-public handoff model no longer functions in biotech. Books must be oversubscribed before listing, requiring crossover public investors to participate in pre-IPO rounds. Of 17 biotech IPOs completed by August 2026, roughly 30-50% upsized their offerings, with the strongest post-debut performance concentrated among clinical-stage companies with multiple assets and near-term catalysts rather than preclinical-stage programs. → NOTABLE MOMENT Strand CEO Jake Beecroft revealed that China's clinical trial dominance is less about China's strengths and more about self-inflicted US inefficiencies. He argued that without urgent reform to IRB processes and clinical site infrastructure, early-stage drug discovery could become structurally uninvestable in America — a framing that reorients the China debate entirely. 💼 SPONSORS None detected 🏷️ Biotech IPOs, FDA Regulatory Decisions, US-China Clinical Trials, Reverse Mergers, IgA Nephropathy, Pharma Mega-Mergers

Read Full Summary Listen

Episode 191 - July 31, 2026

Biotech Hangout

Aug 3, 202660 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 191 covers Q2 2026 biotech sector performance with XBI up 24% year-to-date, reverse merger trends, AI's role in drug discovery, major BD deals including J&J's $785M Sail Biomedicines partnership and argenx's $2.2B Forte acquisition, FDA advisory committee outcomes, and Alnylam's guidance cut on Amvutra. → KEY INSIGHTS - **Biotech Sector Positioning:** XBI is up 24% year-to-date versus S&P 500 at 9% and Nasdaq at 8%, with three structural tailwinds supporting continued outperformance: FDA leadership turnover shifting from headwind to tailwind, 14 US biotech IPOs already surpassing all of 2025's eight, and over $300B in pharma revenue at risk from patent expirations driving sustained M&A demand through the next decade. - **Reverse Merger Mechanics:** Approximately 10 companies went public via reverse merger in 2026, matching or exceeding traditional IPO volume. Investors favor this route because it allows confidential due diligence unavailable in standard IPOs, closes faster amid political uncertainty around midterms, and post-market performance has been strong with deals consistently oversubscribed. Syndicate quality now rivals traditional IPOs, eliminating the prior perception disadvantage. - **AI in Drug Discovery — Agentic Tools Over Molecule Generation:** The real productivity gain from AI in biotech is not computational molecule design but agentic tools like Anthropic's Claude that amplify individual scientists. Tasks previously requiring weeks — writing protocols, designing experiments, analyzing results, drafting papers — now take minutes. Platforms like Cadence added over 150,000 scientists in months, signaling that AI-as-lab-assistant is the near-term transformational application. - **In Vivo CAR-T Deal Landscape:** J&J's $785M upfront partnership with Sail Biomedicines, with an option to acquire for an additional $2.6B, marks J&J's second in vivo CAR-T deal after its Colonia collaboration. Combined with Eli Lilly's $2.4B Orna deal and $7B Colonia deal, the in vivo CAR-T space is consolidating rapidly. Investors should monitor Legend Biotech, which faces CEO departure, Gilead's Anito Cell approval expected in December, and J&J's reduced acquisition incentive. - **FDA Advisory Committees Signal Balanced Standards:** Two high-profile AdComs returned this week: Capricor's Dermiocell for DMD was voted down 3-9, while Replimmune's RP1 for melanoma was approved 10-3. Both outcomes demonstrate that post-Marty Makary FDA leadership is not broadly loosening approval standards. Investors treating leadership turnover as a blanket green light should recalibrate; the agency continues applying rigorous statistical scrutiny, particularly around protocol changes and endpoint measurement methodology. - **Alnylam Amvutra Guidance Cut — Stabilizer vs. Silencer Dynamics:** Alnylam cut Amvutra guidance for the second time in three quarters, sending shares down roughly 30%. The core commercial risk is that community cardiologists may default to cheaper oral stabilizers like Tafamidis when efficacy appears comparable. The Ionis AZ outcomes trial failure on combo benefit reinforces this concern. Alnylam's next-gen silencer outcomes trial, structured as a Tafamidis combo study, now carries elevated risk pending ESC data presentation. → NOTABLE MOMENT Anthropic's Claude Science program sparked speculation that an AI company could acquire a major pharma like Bristol Myers or AbbVie outright. While the panel dismissed the scenario as unlikely, the discussion underscored how rapidly AI capital is accumulating relative to traditional biopharma valuations — a structural dynamic the industry has not previously confronted. 💼 SPONSORS None detected 🏷️ Biotech M&A, XBI Performance, In Vivo CAR-T, FDA Advisory Committees, AI Drug Discovery, Reverse Mergers

Read Full Summary Listen

Episode 185 -June 5, 2026

Biotech Hangout

Jun 9, 202660 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 185 covers ASCO 2026 highlights including PD-1/VEGF bispecifics, RAS inhibitor breakthroughs in pancreatic cancer, CDK4-selective inhibitors in breast cancer, GRAIL's multi-cancer detection trial failure, Abivax's ulcerative colitis safety signal, in vivo CAR-T early data, and the COINS Act debate over US-China biotech investment restrictions. → KEY INSIGHTS - **Biotech market positioning:** Year-to-date XBI is up 8% while semiconductors (SMH) are up 66%, but the 12-month view shows strong biotech recovery driven by M&A activity and a Q4 2025 rebound. Investors should evaluate biotech performance on a trailing 12-month basis rather than year-to-date to avoid misreading sector health amid AI-driven capital rotation. - **RAS inhibition breakthrough in PDAC:** Revolution Medicine's daraxonrasib sets a new standard of care in pancreatic ductal adenocarcinoma, improving median overall survival from 6.7 to 13.2 months versus chemotherapy. The drug targets KRAS G12D/V mutations, which represent roughly 80% of trial patients. Dose reductions manage tolerability issues including rash, stomatitis, and diarrhea without high discontinuation rates. - **CDK4-selective inhibitors outperform CDK4/6 class:** Pfizer's atirmociclib and BioNTech's BNT395 show 60–74% confirmed response rates versus roughly 50–55% for CDK4/6 inhibitors in HR+/HER2- breast cancer. BNT395 eliminates neutropenia by avoiding CDK6 modulation, enabling future combination strategies. Both drugs are now in Phase 3, with readouts expected in two to three years. - **COINS Act expansion risks US competitiveness:** Proposed BINZA legislation and a congressional letter from Representative Moolenaar would restrict US capital flows and licensing deals with Chinese biotechs. Panelists argue this benefits European pharma and funds, who face no equivalent restrictions, while slowing US patient access to medicines. The more defensible national security focus should target manufacturing supply chain dependency, not innovation licensing. - **GRAIL multi-cancer detection trial misses primary endpoint:** The MCED trial failed to show statistically significant reduction in Stage 3 and 4 cancers at three-year follow-up, with an IRR slightly above one. A 14% reduction in Stage 4 cancers was offset by an increase in Stage 3 detections. Test specificity and positive predictive value (~52%) remain strong, but the data raises unresolved questions about whether early detection translates to mortality improvement. - **In vivo CAR-T shows early promise with durability caveats:** Lilly's Colonya (formerly Cabaletta) demonstrated 100% ORR and MRD negativity in 18 relapsed/refractory multiple myeloma patients, but one patient relapsed and another turned MRD-positive by month three. Legend Biotech's lymphoma in vivo CAR-T showed 100% response rate and 83% complete responses at the higher dose level across six patients, with only Grade 1–2 toxicity at 2.2-month median follow-up. → NOTABLE MOMENT Abivax's ulcerative colitis maintenance data showed efficacy exceeding the 30% placebo-adjusted benchmark, yet the stock dropped 45% after seven malignancy cases emerged at the high dose versus one on placebo. Panelists noted the patient population carries elevated baseline cancer risk, similar to JAK inhibitors carrying black box warnings, but the dose-concentration pattern remains a regulatory overhang. 💼 SPONSORS None detected 🏷️ ASCO 2026, PD-1 VEGF Bispecifics, KRAS Inhibition, CDK4 Selective Inhibitors, COINS Act China Biotech, Multi-Cancer Early Detection

Read Full Summary Listen

Episode 184 - May 29, 2026

Biotech Hangout

May 29, 202658 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 184 covers the 2026 IPO market health with 11 filings by May, Ginkgo Bioworks CEO Jason Kelly's national security argument against offshoring biotechnology to China, Eli Lilly's three vaccine acquisitions totaling $3.8B, and key ASCO oncology data previews including Revolution Medicines' pancreatic cancer results. → KEY INSIGHTS - **Biotech IPO benchmark:** Eleven biotech IPOs filed by end of May 2026 already matches or exceeds all of 2025's total. Investor sentiment index reached 120 among finance and investment stakeholders in Q2 2026, up from 78 in Q4 2025. Later-stage clinical assets with phase 2b data characterize this cycle, distinguishing it from frothier preclinical-heavy prior waves. - **China offshoring risk framework:** Massachusetts lost 1,100 biotech R&D jobs in 2024, the first such decline MassBio has recorded, with one-third of lab space now vacant. Jason Kelly frames this as structural offshoring of genetic engineering capability, not cyclical decline. Investors and biotechs should monitor whether discovery-stage science, not just manufacturing, is migrating to China. - **Alternative financing structure:** Apogee Biosciences secured up to $1.3B from Blackstone Life Sciences concurrent with positive phase 2 atopic dermatitis data, bypassing traditional equity follow-on raises entirely. The deal splits into $800M synthetic royalty financing and $500M senior debt. Biotechs with late-stage assets should evaluate royalty-based non-dilutive structures as a capital-raising alternative to bank-led offerings. - **RAS inhibitor efficacy bar:** Revolution Medicines' daraxonrasib achieved 13.2 months median overall survival in second-line pancreatic cancer versus 6.7 months for standard chemotherapy in the phase 3 RESOLUTE-302 study. Full data present at ASCO 2026 plenary. Companies developing follow-on pan-RAS inhibitors, including Rasca and Verastem, now face this doubling of survival as the competitive efficacy threshold to clear. - **Myostatin combination strategy for obesity:** Biohaven's myostatin antibody teldafrecapap alpha, combined with semaglutide, targets the body composition problem of GLP-1 therapies, where significant muscle mass loss accompanies fat loss. Phase 2 data are forthcoming. Investors tracking obesity pipeline should assess combination approaches preserving lean mass, particularly as Lilly's bimagramab showed tolerability issues and appears to have stalled development. → NOTABLE MOMENT Jason Kelly argued that the pharmaceutical drug market is not a free market, citing that US consumers representing 4% of the global population generate 70% of industry profits. This gives the US unique leverage to set industry rules that China and European intermediaries cannot circumvent through deal structuring. 💼 SPONSORS None detected 🏷️ Biotech IPOs, China Biotech Policy, ASCO 2026, Obesity Pipeline, Hepatitis B Treatment

Read Full Summary Listen

Episode 177 - March 27, 2026

Biotech Hangout

Mar 27, 202656 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout Episode 177 covers the week of March 27, 2026, examining roughly $10 billion in M&A activity including Gilead's $2.2 billion Ouro acquisition and Merck's $6 billion Tern deal, alongside FDA regulatory shifts post-Vinay Prasad, and clinical data from Beam, Sarepta, and Maze Therapeutics. → KEY INSIGHTS - **Biotech relative performance:** XBI is up approximately 2% year-to-date while the S&P 500 is down 6%, an 8-percentage-point spread in three months. Investors tracking sector rotation should note biotech outperforms on up days by roughly 4x the S&P and declines less on down days, suggesting sustained institutional appetite despite macro uncertainty. - **FDA approval pace shift:** Following Vinay Prasad's departure from CBER, the FDA approved three drugs in one week — Denali's Avolaya for Hunter Syndrome, Rocket's gene therapy for LAD-1, and Imvax's Lofurli — several ahead of PDUFA dates. Companies with orphan or rare disease applications should consider filing now while regulatory flexibility appears elevated under commissioner pressure. - **Oral psoriasis market expansion:** J&J's icicotide approval plus upcoming AAD data from Alumis and Takeda signal the first genuinely efficacious oral psoriasis therapies. Dermatology investors should model market expansion from $20–30 billion toward $40+ billion as millions of patients currently using only topicals gain access to convenient, biologic-comparable oral options. - **Tern/Merck acquisition premium warning:** Merck acquired Tern Pharmaceuticals — developer of TRN-701, a best-in-class CML drug comparable to Novartis' Scemblix — at only a 6% premium to market price. Biotech boards and investors should scrutinize low-premium acquisitions carefully, as selling at market price eliminates future optionality that existing shareholders may have already priced in. - **APOL1 kidney disease market sizing risk:** Maze Therapeutics' MZ-829 data showed strong UPCR reductions in FSGS patients with two APOL1 alleles but minimal effect in diabetic APOL1 patients, sending the stock down 40%. Investors in Vertex's enaxaplan Phase 3 program should reassess addressable market assumptions — the opportunity may be closer to FSGS-only patients than the 250,000-patient APOL1-broad estimate. → NOTABLE MOMENT A single patient in Beam Therapeutics' AATD base-editing trial developed an infection post-treatment — typically dangerous for this condition — yet the corrected gene automatically upregulated healthy protein production in response, demonstrating that the therapy restored natural biological stress response rather than simply supplementing a missing protein. 💼 SPONSORS None detected 🏷️ Biotech M&A, FDA Regulation, Gene Editing, Psoriasis Therapeutics, APOL1 Kidney Disease

Read Full Summary Listen

Episode 165 - December 5, 2025

Biotech Hangout

Dec 5, 202561 minCohost

AI Summary

→ WHAT IT COVERS Biotech analysts examine 2026 sector outlook following strong 2025 rally, discussing FDA leadership changes under Rick Pazdur's resignation, regulatory uncertainty for rare disease therapies like UniQure's Huntington's treatment, IPO market predictions ranging from 15 to 50 companies, vaccine policy controversies, and competitive dynamics affecting data disclosure practices in oncology development. → KEY INSIGHTS - **2026 Sector Outlook:** Biotech enters third inning of rally after strong 2025 recovery, with XBI still below all-time highs despite recent gains. Key positive factors include successful drug launches from mid-sized companies like Insmed and Madrigal proving commercial viability, minimal drug pricing threats, and expected M&A activity. Primary remaining risk centers on FDA unpredictability, particularly for rare disease approvals with unvalidated endpoints. - **IPO Market Predictions:** Analysts forecast 15 to 50 biotech IPOs in 2026, significantly lower than the 100-plus peak during 2020-2022. Current pipeline features mid-to-late stage companies with derisked assets, contrasting sharply with previous cycle when companies filed S-1s with IND acceptance as primary catalyst. Public investors now participating in private rounds enables better incubation, creating institutionally relevant companies rather than illiquid venture investments. - **FDA Leadership Vacuum:** Rick Pazdur's resignation after three weeks as CDER director removes last senior FDA official with decades of institutional memory. CBER CSO Vinay Prasad actively inserting himself into approval decisions despite claims otherwise, creating unpredictability. Companies seeking CBER approvals should attempt direct engagement with Prasad and request his signature on meeting minutes to ensure alignment, though accessibility remains questionable. - **Rare Disease Regulatory Risk:** UniQure's Huntington's gene therapy faces approval rejection despite May breakthrough designation and agreed statistical analysis plan, with November FDA reversal attributed to leadership changes. Single-arm pivotal trials with natural history controls face heightened scrutiny under new leadership. Companies with pre-specified endpoints showing unprecedented efficacy on validated measures remain lower risk than slowly progressive diseases with functional endpoints. - **Vaccine Policy Controversy:** HHS and FDA pushing back against childhood vaccination schedules, with ACIP negative vote on at-birth hepatitis B vaccination receiving criticism. COVID vaccines remain flashpoint because they touch every healthy person, carry risks like myocarditis, and face social media amplification of safety questions. Passive immunity approaches using monoclonal antibodies from companies like Sanofi and Convivid may offer alternative without vaccine baggage. - **Competitive Data Disclosure:** Janex Therapeutics stock dropped 50 percent after selective PSMA bispecific data presentation, citing competitive dynamics with Chinese biotech as justification for withholding details. Management argues full disclosure enables competitors to draft off hard-won platform learnings. Investors generally discount opacity negatively, with only management teams having earned substantial trust able to maintain credibility through limited transparency in highly competitive spaces. → NOTABLE MOMENT Capricor's positive phase three data for allogeneic cardiosphere-derived cells in Duchenne muscular dystrophy sparked debate about mechanism requirements for approval. Despite unclear biology, analysts argued the first clean randomized controlled trial success in this population warrants approval, especially given numerous approved drugs with unknown mechanisms in psychiatry and neurology. Stock surged 400 percent on results. 💼 SPONSORS None detected 🏷️ FDA Regulatory Policy, Biotech IPO Market, Gene Therapy Approvals, Vaccine Controversy, China Biotech Competition, Rare Disease Development

Read Full Summary Listen

Episode 168 - January 9, 2026

Biotech Hangout

Jan 9, 202661 minCohost

AI Summary

→ WHAT IT COVERS Biotech Hangout opens 2026 with analysis of strong sector momentum driven by M&A activity, successful IPOs, and positive market sentiment. The XBI trades at 2125, matching November 2021 levels. Discussion covers Revolution Medicine takeover rumors, Actis Pharmaceuticals IPO raising $318 million, emerging obesity mechanisms beyond GLP-1s, and policy concerns including CDC vaccine schedule changes and CMS pricing demonstrations. → KEY INSIGHTS - **M&A Market Dynamics:** Revolution Medicine attracts competing bids from AbbVie and Merck at $28-32 billion valuation, representing premium multiples versus historical oncology deals like Loxo and Array. This follows AstraZeneca's $100 million upfront deal with China's Jacobio for a pan-RAS inhibitor and Lilly's VTYX acquisition. Multiple pan-RAS programs validate the target class, with RevMed's phase 3 pancreatic cancer asset potentially reaching market within two years in high unmet need indication. - **IPO Window Reopens:** Actis Pharmaceuticals prices at $18 versus $16-18 range, raises $318 million including $100 million from partner Lilly, and opens at $27 with 10x oversubscription. The radioligand therapy company uses novel mini-protein discovery platform rather than existing peptides, targeting NECTIN-4 initially. Last private raise was $175 million series B in September 2024 from RA Capital, RTW, Janus Henderson, with additional backing from T. Rowe Price, Avidity, Lilly, Bristol Myers, and Merck ventures. - **Follow-On Financing Surge:** Companies pull secondary offerings earlier than traditional post-JPMorgan timing, with all deals upsizing and trading double-digit percentages above offer price. Crynetics raises capital following Pulsenify launch exceeding consensus with 200 enrollment forms in first full quarter for niche indication, plus positive congenital adrenal hyperplasia phase 2 data showing glucocorticoid reduction. Strong follow-on performance indicates robust capital availability and investor enthusiasm entering 2026. - **Next-Generation TYK2 Inhibitors:** Alumis demonstrates envudacitinib achieves PASI 90 in over 50% of psoriasis patients and PASI 100 in 30-40%, matching J&J's oral IL-23 inhibitor icotrokinra and rivaling biologic efficacy. Takeda's TYK279 shows similar results, reframing oral small molecule potential after Bristol's Sotyktu commercial disappointment. Second-generation TYK2s avoid first-generation liabilities while expanding into psoriatic arthritis, ulcerative colitis, and SLE, with Bristol and Alumis both reporting phase 3 SLE data in 2026. - **Obesity Beyond GLP-1:** Arrowhead raises upsized $625 million following ARO-INHBE phase 2 data showing strong efficacy in diabetic obese patients when combined with tirzepatide, despite minimal monotherapy effect in non-diabetic obesity. The siRNA approach targets visceral adipose tissue and liver fat content through novel pathway distinct from GLP-1 mechanisms. Wave Life Sciences pursues similar strategy. Regulatory pathway remains unclear given combination-dependent efficacy, but market validates novel mechanisms addressing muscle preservation and metabolic health beyond weight loss alone. - **Policy Overhang Persists:** CDC removes six vaccines from recommended pediatric schedule without ACIP discussion, including rotavirus, COVID, influenza, meningococcal, hepatitis A, and reduces HPV to single dose. Insurance coverage remains unchanged, limiting immediate commercial impact. CMS most-favored-nation demonstration announcement generates minimal market reaction, suggesting investors either dismiss implementation probability or underestimate impact. Market resilience to policy headlines creates downside risk if significant pricing reform materializes, as investor desensitization may delay appropriate risk assessment. → NOTABLE MOMENT Zenas BioPharma's obexelimab data for IgG4-related disease showed only 56% flare reduction versus Uplizna's 87% in cross-trial comparison, despite positive headline framing. The CD19/FcRIIb dual-targeting mechanism failed to demonstrate superiority over CD19-only approach, disappointing investors expecting enhanced potency from co-engagement strategy. The company proceeds with FDA and EMA filings, positioning weekly subcutaneous dosing as differentiation versus Uplizna's intravenous administration. 💼 SPONSORS [{"name": "CFGO", "url": ""}, {"name": "Incubate Coalition", "url": ""}, {"name": "FTI Consulting", "url": ""}, {"name": "Catalytic Agency", "url": ""}, {"name": "MISPRO", "url": ""}] 🏷️ Biotech M&A, IPO Markets, TYK2 Inhibitors, Obesity Therapeutics, Drug Pricing Policy, Vaccine Policy

Read Full Summary Listen

Frequently Asked Questions

What podcasts has Brian Skorney appeared on?

Brian Skorney has appeared on 1 podcast we summarize, including Biotech Hangout — 10 episodes in total. Every appearance is listed below with an AI-generated summary.

Does Brian Skorney appear as a guest speaker on podcasts?

Yes. Brian Skorney has been a guest on 1 show we track, across 10 episodes. Browse each appearance below to read the key takeaways and listen to the original.

Where can I find summaries of Brian Skorney's interviews?

Read AI-generated summaries of all 10 of Brian Skorney's podcast appearances on SignalCast — each with key insights and a link to the full episode.

Never miss Brian Skorney's insights

Subscribe to get AI-powered summaries of Brian Skorney's podcast appearances delivered to your inbox weekly.

Start Free Today

No credit card required • Free tier available